BlackRock Inc. increased its stake in Amedisys Inc (NASDAQ:AMED) by 2,877.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,676,870 shares of the health services provider’s stock after buying an additional 5,486,225 shares during the period. BlackRock Inc.’s holdings in Amedisys were worth $290,032,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can increased its stake in Amedisys by 8.0% in the first quarter. Great West Life Assurance Co. Can now owns 40,062 shares of the health services provider’s stock valued at $2,045,000 after buying an additional 2,960 shares during the period. Monarch Partners Asset Management LLC bought a new stake in Amedisys during the first quarter valued at approximately $8,984,000. First Midwest Bank Trust Division increased its stake in Amedisys by 3.0% in the first quarter. First Midwest Bank Trust Division now owns 34,740 shares of the health services provider’s stock valued at $1,775,000 after buying an additional 1,012 shares during the period. Russell Investments Group Ltd. increased its stake in Amedisys by 77.7% in the first quarter. Russell Investments Group Ltd. now owns 36,295 shares of the health services provider’s stock valued at $1,854,000 after buying an additional 15,875 shares during the period. Finally, State of Alaska Department of Revenue increased its stake in Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock valued at $157,000 after buying an additional 70 shares during the period. 97.81% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Inc (NASDAQ:AMED) traded up 3.21% during mid-day trading on Friday, reaching $48.56. The company had a trading volume of 440,765 shares. The firm has a market capitalization of $1.64 billion, a PE ratio of 41.50 and a beta of 0.89. Amedisys Inc has a 52 week low of $34.58 and a 52 week high of $65.91. The stock’s 50-day moving average price is $59.50 and its 200 day moving average price is $54.23.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.12. The firm had revenue of $378.80 million during the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.42 EPS. On average, equities research analysts predict that Amedisys Inc will post $2.21 EPS for the current year.

WARNING: “BlackRock Inc. Buys 5,486,225 Shares of Amedisys Inc (NASDAQ:AMED)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/04/blackrock-inc-boosts-position-in-amedisys-inc-nasdaqamed-updated-updated-updated.html.

Several research analysts have recently weighed in on the company. Royal Bank Of Canada restated a “hold” rating and issued a $56.00 price target on shares of Amedisys in a research note on Monday, June 5th. Mizuho cut Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price target for the company. in a research note on Wednesday, July 26th. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Stephens boosted their price target on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 4th. Finally, Benchmark Co. restated a “hold” rating and issued a $57.00 price target (up previously from $50.00) on shares of Amedisys in a research note on Wednesday, May 3rd. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $56.50.

In other Amedisys news, Director Jake L. Netterville sold 10,000 shares of Amedisys stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the sale, the director now owns 77,499 shares of the company’s stock, valued at approximately $4,649,940. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bruce D. Perkins purchased 500 shares of the stock in a transaction on Thursday, May 25th. The shares were purchased at an average cost of $59.69 per share, with a total value of $29,845.00. Following the transaction, the director now owns 13,331 shares in the company, valued at approximately $795,727.39. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 56,828 shares of company stock valued at $3,350,922. 2.80% of the stock is currently owned by insiders.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.